COVID-19 and Dermatologic Manifestations: What We Know So Far
Esther Freeman, MD, PhD, talks about the various levels of dermatologic severity associated with COVID-19.
Esther Freeman, MD, PhD, talks about the various levels of dermatologic severity associated with COVID-19.
This interview with Bunick featured a discussion of his team’s recent data comparing anti-IL-23 biologics, epitopes, and comparisons with risankizumab.
The decision by Eli Lilly to resubmit lebrikizumab to the FDA for adults and adolescents with eczema is expected to receive a response in the…
Among the nurse-led cohort, 83% of patients with gout achieved target p-urate levels and 98% continued treatment with urate lowering therapy.
These data allow for a basis for additional research and possible interventions to address psoriasis patients’ demodicosis risk.
HCPLive is a comprehensive clinical news and information portal that provides physicians with up-to-date specialty and disease-specific resources designed to help them provide better care…
Abbott’s Esprit BTK System was shown to significantly reduce risk of ischemic events in patients with PAD versus angioplasty over 1 year.
FDA approves mavorixafor (XOLREMDI) for WHIM syndrome, the first approved treatment for the rate disease.
The announcement by Dermavant followed positive findings from the ADORING trials on tapinarof and an open label extension for children aged 2 – 17.
During this discussion, Ohuabunwa discussed additional takeaways from her ACP conference talk on postdischarge care and other tips for internal medicine physicians.
After being prescribed another urate lowering therapy for ≥ 30 days, only 51.0% of patients were able to achieve SU < 6 mg/dL.